Clinical Trials for Cancer Type: Prostate

15 Open Trials. Phone:(877.827.8839)
Protocol No. Title Status
ECOG-EAY131 (CIRB) Molecular Analysis for Therapy Choice (MATCH) Open
SWOG-S1609 (CIRB) DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors Open
UCI-06-13 Evaluation of Predictive Signatures of Prostate Cancer Open
UCI-14-65 Phase II Randomized, Placebo-Controlled Trial of PROSTVAC (PSA-TRICOM) in Patients with Clinically Localized Prostate Cancer Undergoing Active Surveillance Open
UCI-14-90 Biomarkers and Clinical Parameters Associated with Gleason Score Upgrading Open
UCI-15-52 A Phase 3, Randomized, Efficacy and Safety Study of Enzalutamide Plus Leuprolide, Enzalutamide Monotherapy, and Placebo Plus Leuprolide in Men With High Risk Nonmetastatic Prostate Cancer Progressing After Definitive Therapy Open
UCI-15-70 Small Nucleolar RNAs (snoRNAs) And Alternative Splicing In Castration-Resistant Prostate Cancer: A Potential Role In Regulation Of Androgen Receptor Signaling Open
UCI-16-19 ATLAS: A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy Open
UCI-16-76 Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365) Open
UCI-16-90 A Phase III, Multicenter, Randomized Study Of Atezolizumab (Anti-PD-L1 Antibody) In Combination With Enzalutamide Versus Enzalutamide Alone In Patients With Metastatic Castration-Resistant Prostate Cancer After Failure Of An Androgen Synthesis Inhibitor And Failure Of, Ineligibility For, Or Refusal Of A Taxane Regimen Open
UCI-16-96 A Phase 1 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors Open
UCI-17-07 Patient Reported Outcomes via Online Questionnaire (PROVOQ): Post-Radical Prostatectomy Outcome Assessment Open
UCI-17-10 A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib plus Abiraterone plus Prednisone/Prednisolone, Relative to Placebo plus Abiraterone plus Prednisone/Prednisolone in Adult Male Patients with Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer Open
UCI-17-40 Precision Medicine for Early Prostate Cancer: Integrating Biological and Patient Complexity Variables to Predict Treatment Response Open
UCI-98-41 Outcomes and Assessment of Prostate Cancer at UCIMC Open